Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunovant, Inc.HSAC · Entity 3632 | Director | May 09, 2019 | May 10, 2019 |
| TG THERAPEUTICS, INC.TGTX · Entity 3608 | Director | June 26, 2018 | June 28, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunovant, Inc.
Report date May 09, 2019 · Filed May 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy way of Health Sciences Holdings, LLC. | 20,000 |
Reported balance
Holding disclosure · report date 2019-05-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 20,000 |
TG THERAPEUTICS, INC.
Report date June 26, 2018 · Filed June 28, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 125,949 |
Reported balance
After 2018-06-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-06-26 · Grant · Acquired 15,000 · Balance 125,949 F1: Reflects a grant of restricted shares that will vest on June 26, 2021. F2: Includes shares of restricted Common Stock, which vest over various time periods. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted shares that will vest on June 26, 2021.
F2: Includes shares of restricted Common Stock, which vest over various time periods.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2018 Filed Jun 28, 2018 21:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-18-007117 · section16.xml · nonDerivative · entry 1 SCHOENEBAUM MARK · CIK 0001548537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,949 F1 · shares: Reflects a grant of restricted shares that will vest on June 26, 2021. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 16, 2017 Filed Jun 19, 2017 22:06 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-17-005703 · section16.xml · nonDerivative · entry 1 SCHOENEBAUM MARK · CIK 0001548537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,949 F1 · kind: Reflects a grant of restricted shares that will vest on June 16, 2020. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.